ClinicalTrials.gg
TerminatedNCT00751036MACS0375Updated Mar 26, 2014Results posted

Nilotinib 800 Mg And Imatinib 800 Mg For The Treatment Of Patients With Gastrointestinal Stromal Tumors (Gist) Refractory To Imatinib 400 Mg

A Phase 3 interventional study of Nilotinib and Imatinib in Gastrointestinal Stromal Tumors, sponsored by Novartis Pharmaceuticals. Terminated at 32 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nilotinib in Gastrointestinal Stromal Tumors — none open to participants now, none under way, none of them phase 3. nilotinib · Gastrointestinal Stromal Tumors.

Enrollment
4th of 14
94 · median 35
Started
2009
with 1 other
Phase 3
4 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
12 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 6th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

None of the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors is open now. The open studies under Gastrointestinal Stromal Tumors, anywhere →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing nilotinib in Gastrointestinal Stromal Tumors as a file.
02

Study summary

The study will investigate the comparative efficacy and safety of two oral inhibitors of Kit and PDGFR: nilotinib 400 mg bid, a novel agent, and imatinib 400 mg bid, an approved agent with an established efficacy.

Read the detailed description

This is an international, randomized, open-label, double-arm, phase III trial that will be conducted in centers in Latin America, Asia, Europe and Canada. The study will be sponsored by Novartis Pharmaceuticals Corporation. Patient enrollment will be competitive and will have a duration of up to 30 months. An interim analysis is planned to occur when approximately 60% of the PFS events occurs. A total of 150 patients per arm will be enrolled in the study. Eligible patients will have advanced/metastatic, inoperable GIST of any anatomical location or recurrent GIST while on or post imatinib adjuvant therapy, with documented disease progression on therapy with imatinib 400 mg q.d.

03

Conditions studied

  • Gastrointestinal Stromal Tumors

Keywords

  • GIST
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide a written .
  • Male or female patients ≥ 18 years of age.
  • confirmed diagnosis of GIST of any anatomical location, which is unresectable and/ or or recurrent.
  • Documented disease progression according to 1.0. Documentation of progression required by either 2 CT scans or 2 MRI scans within 6 months prior to randomization (one image will document the lesion and the other will document the progression by lesion(s) growth or the presence of new lesion(s)). The interval between the 2 images should be no greater than 6 months apart. Scans will be provided to the selected imaging CRO.
  • Documented disease progression must occur while on imatinib 400 mg PO q.d. Imatinib therapy could be for (1) unresectable GIST; (2) metastatic GIST; or (3) recurrent GIST while on imatinib therapy or recurrent GIST post adjuvant imatinib therapy.
  • Positive immunohistochemical staining for c-KIT (CD117) or negative staining for KIT, but with either positive staining for DOG1 or an identified mutation on KIT or PDGFR genes.
  • Presence of at least one according to RECIST 1.0, defined as a lesion that can be accurately measured in at least one dimension (longest diameter) as ≥ 20 mm with conventional techniques (conventional CT or MRI scan) or as ≥ 10 mm with spiral CT scan. Lesions in previously irradiated areas can be considered measurable only if they have demonstrated clear evidence of progression since the radiotherapy.
  • A performance status of 0, 1 or 2 according to the (ECOG) scale (Oken et al 1982)(Appendix A).
  • Adequate organ function, as indicated by all of the following:
  • White blood cell (WBC) count ≥ 3500/mm3;
  • (ANC) ≥1500/mm3;
  • ≥ 9.0 g/dL;
  • count ≥ 100 x 109/L;
  • Total ≤ 1.5 X (\< 3.0 X ULN if related to disease);
  • (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the ULN, unless liver metastases present, in which case AST and ALT have to be ≤ 5 times the ULN;
  • Serum creatinine ≤ 1.5 times the ULN;
  • Serum amylase and lipase ≤1.5 X ULN;
  • Alkaline phosphatase ≤2.5 X ULN (≤ 5.0 X ULN if related to disease);
  • Serum potassium, phosphorus, magnesium and calcium ≥ LLN [lower limit of normality] or correctable with supplements prior to first dose of study drug. (Total calcium corrected for serum albumin)
  • Female patients of must have a negative serum pregnancy test within 7 days prior to registration.
  • Fertile patients (female) must agree to use an acceptable method of to avoid pregnancy for the duration of the study and for 3 months after study termination.

Exclusion criteria

Exclusion Criteria:

  • Prior use of imatinib doses higher than 400 mg q.d. or prior use of any other tyrosine-kinase inhibitor.
  • Tumor progression after stopping imatinib 400 mg q.d.
  • No cytotoxic drug ≤ 4 weeks (6 weeks for nitrosurea or mitomycin C) prior to the Screening Visit (V100) is allowed with the exception of imatinib therapy.
  • Cytotoxic, or antineoplastic treatments, such as chemotherapy, immunotherapy, biological response modifiers, or radiotherapy.
  • If the only was previously irradiated and has not shown clear evidence of progression since the radiotherapy, the patient cannot be included.
  • Serious uncontrolled concomitant medical or psychiatric illness.
  • Impaired cardiac function including any one of the following:
  • \< 45% or below the institutional lower limit of the normal range (whichever is higher) confirmed by ECHO or Muga
  • Inability to determine the on
  • Complete left bundle branch block
  • Right bundle branch block plus left anterior or posterior hemiblock
  • Use of a ventricular-paced pacemaker
  • Congenital long QT syndrome or a known family history of long QT syndrome
  • History of or presence of ventricular or atrial tachyarrhythmias
  • Clinically significant resting bradycardia (\<50 bpm);
  • QTcF >450 msec on screening ECG (using the QTcF formula). If QTc >450 and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc;
  • History or clinical signs of myocardial infarction within 1 year of study entry
  • History of unstable angina within 1 year of study entry
  • Other clinically significant heart disease (e.g., congestive heart failureor uncontrolled hypertension).
  • Treatment with strong inhibitors (e.g., erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil) and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. (Appendix B).
  • Treatment with strong CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbitol, St John's Wort), and the treatment cannot be discontinued or switched to a different medication prior to starting study drug.
  • Patients using medication that have been documented to prolong QT interval (see Appendix B for complete list).
  • Grade 3 or higher impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome).
  • History of acute pancreatitis within one year of study entry or medical history of chronic pancreatitis.
  • Patients with a history of another primary that is currently clinically significant or currently requires active intervention.
  • Patients with any other clinically significant medical or surgical condition which, according to investigators' discretion, should preclude participation; (i.e.: severe renal disease unrelated to tumor, active or chronic liver disease- or C virus carriers with normal liver function tests, as described above, can be included). This includes patient with an acquired bleeding disorder unrelated to cancer.
  • Use of any investigational agent within 28 days prior to enrollment in the study or foreseen use of an investigational agent during the study.
  • History of non-compliance to medical regimens or inability to grant consent.
  • Women who are pregnant, breast feeding, or of without a negative serum pregnancy test at baseline. Male or female patients of childbearing potential unwilling to use effective barrier throughout the trial and for 3 months following discontinuation of study drug. women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
  • Inability to comply with the study protocol.
  • Patients with a history of . Note: Patients without clinical signs and symptoms of CNS involvement are not required to have CT/MRI of the brain.
  • Major surgery within 4 weeks prior to randomization or those who have not recovered from prior surgery

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Patients who were assigned to this treatment group received 400 mg. nilotinib bid.

    Drug: Nilotinib

  • Active comparator
    Imatinib

    Patients who were assigned to this treatment group received 400 mg. imatinib bid.

    Drug: Imatinib

Interventions

  • Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.

    Also known as: Tasigna

  • Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.

    Time frame: 24 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    The Disease Control Rate (Complete Response(CR), Partial Response (PD) and Stable Disease (SD) rates for each treatment arm will be computed using the exact Clopper-Pearson interval estimation methodology. DCR is defined as the percentage of patients with a best overall response of • CR, i.e. at least two determinations of CR at least 4 weeks apart without loss of response between the determinations, • PR, i.e. at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) and without loss of PR between the determinations, or • SD lasting at least 24 weeks, i.e. at least one SD or better response at least 24 weeks after randomization (and not qualifying for CR or PR).

    Time frame: every 2 months until 24 months (end of study)

  2. Time to Treatment Failure

    TTF, defined as the time from date of randomization to the earliest of date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'.

    Time frame: Time from date of radomization to the earliest date of the first objective tumor, death or discontinuation, assesed until 24 months.

  3. Overall Survival (OS)

    . OS is defined as the time from the date of randomization to the date of death due to any cause or the date of last contact prior to or on the date of data cutoff. The median time to overall survival and its associated 95 % CI will be derived, for each treatment arm, using the time to event analysis based on Kaplan-Meier methodology.

    Time frame: time from the date of randomization to the date of death due to any cause or the date of last contact prior to or on the date of data cutoff, assesed until 24 months.

07

Results

Posted Mar 26, 2014
Limitations and caveats
Patients were limited (planned 300, Actual 94). Early termination of study; not sufficient power to test the original primary hypothesis with respect to PFS. Only descriptive analyses were carried out for this study.

Participant flow

Participant flow — Overall Study
MilestoneNilotinibImatinib
Started4846
Completed00
Not completed4846
Withdrew: Disease progression2829
Withdrew: Adverse event64
Withdrew: Administrative problems34
Withdrew: Withdrawal by subject52
Withdrew: Death33
Withdrew: Lost to follow-up01
Withdrew: Protocol violation10
Withdrew: Missing end of treatment page23

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival (PFS) is the time from date of randomization to the date of first documented progression or death due to any cause. If a participant has not had an event, progression-free survival is censored at the time of last adequate tumor assessment. Progression is defined according to modified RECIST criteria as at least a 20% increase in the sum of the longest diameter of target lesions, worsening of the non-target lesions or the appearance of one or more new lesions.

Time frame:
24 months
Reported as:
Median · Days
Progression-free Survival (PFS)
DaysNilotinibImatinib
Progression-free Survival (PFS)111.00 (83.00 to 190.00)120.00 (59.00 to 173.00)
SecondaryDisease Control Rate (DCR)

The Disease Control Rate (Complete Response(CR), Partial Response (PD) and Stable Disease (SD) rates for each treatment arm will be computed using the exact Clopper-Pearson interval estimation methodology. DCR is defined as the percentage of patients with a best overall response of • CR, i.e. at least two determinations of CR at least 4 weeks apart without loss of response between the determinations, • PR, i.e. at least two determinations of PR or better at least 4 weeks apart before progression (and not qualifying for a CR) and without loss of PR between the determinations, or • SD lasting at least 24 weeks, i.e. at least one SD or better response at least 24 weeks after randomization (and not qualifying for CR or PR).

Time frame:
every 2 months until 24 months (end of study)
Reported as:
Number · Percentage of Patients
Disease Control Rate (DCR)
Percentage of PatientsNilotinibImatinib
Disease Control Rate (CR, PR, or SD)54.2 (39.2 to 68.6)47.8 (32.9 to 63.1)
Complete Response (CR)2.1 (0.1 to 11.1)0 (0 to 7.7)
Partial Response (PR)4.2 (0.5 to 14.3)6.5 (1.4 to 17.9)
Stable Disease (SD)47.9 (33.3 to 62.8)41.3 (27.0 to 56.8)
Progressive Disease (PD)25.0 (13.6 to 39.6)37.0 (23.2 to 52.5)
Unknown (UNK)20.8 (NA to NA)15.2 (NA to NA)
SecondaryTime to Treatment Failure

TTF, defined as the time from date of randomization to the earliest of date of the first objective tumor progression, date of death due to any cause, or date of discontinuation due to reasons other than 'Protocol deviation' or 'Administrative problems'.

Time frame:
Time from date of radomization to the earliest date of the first objective tumor, death or discontinuation, assesed until 24 months.
Reported as:
Median · Days
Time to Treatment Failure
DaysNilotinibImatinib
Time to Treatment Failure90.00 (56.00 to 166.00)112.00 (58.00 to 171.00)
SecondaryOverall Survival (OS)

. OS is defined as the time from the date of randomization to the date of death due to any cause or the date of last contact prior to or on the date of data cutoff. The median time to overall survival and its associated 95 % CI will be derived, for each treatment arm, using the time to event analysis based on Kaplan-Meier methodology.

Time frame:
time from the date of randomization to the date of death due to any cause or the date of last contact prior to or on the date of data cutoff, assesed until 24 months.
Reported as:
Median · Days
Overall Survival (OS)
DaysNilotinibImatinib
Overall Survival (OS)737 (342.00 to NA)594.00 (357.00 to NA)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib 800 mg—12/48 (25%)39/48 (81.3%)
Imatinib 800 mg—10/46 (21.7%)41/46 (89.1%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventNilotinib 800 mgImatinib 800 mg
Abdominal painGastrointestinal disorders2/481/46
Disease progressionGeneral disorders2/481/46
Gastrointestinal stromal tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/481/46
NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/480/46
Cardiac failureCardiac disorders0/481/46
Cardiopulmonary failureCardiac disorders1/481/46
Abdominal massGastrointestinal disorders0/481/46
Enterocutaneous fistulaGastrointestinal disorders0/481/46
Gastrointestinal haemorrhageGastrointestinal disorders0/481/46
Gastrointestinal obstructionGastrointestinal disorders0/481/46
Most frequent other events
Showing 10 of 46
Most frequent other events
EventNilotinib 800 mgImatinib 800 mg
NauseaGastrointestinal disorders12/4820/46
AnaemiaBlood and lymphatic system disorders14/4815/46
DiarrhoeaGastrointestinal disorders4/4814/46
VomitingGastrointestinal disorders10/4813/46
FatigueGeneral disorders10/4812/46
Abdominal painGastrointestinal disorders8/4811/46
Decreased appetiteMetabolism and nutrition disorders6/4810/46
Face oedemaGeneral disorders0/489/46
Oedema peripheralGeneral disorders3/489/46
White blood cell count decreasedInvestigations2/488/46

Baseline characteristics

Age, Customized
Age, Customized(Participants)NilotinibImatinibTotal
<65 years383573
≥ 65 years91120
Missing101
Sex: Female, Male
Sex: Female, Male(Participants)NilotinibImatinibTotal
Female281947
Male202747
08

Study locations

32 sites
  • Novartis Investigative Site
    Caba, Buenos Aires C1426ANZ, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1264AAA, Argentina
  • Novartis Investigative Site
    Fortaleza, CE 60430-230, Brazil
  • Novartis Investigative Site
    Belo Horizonte, MG 30130-100, Brazil
  • Novartis Investigative Site
    Divinopolis, MG 35500-000, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, RJ 20230-130, Brazil
  • Novartis Investigative Site
    Natal, RN 59040-000, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90020-090, Brazil
  • Novartis Investigative Site
    Porto Alegre, RS 90610-000, Brazil
  • Novartis Investigative Site
    Barretos, SP 14784-400, Brazil
  • Novartis Investigative Site
    São Paulo, SP 01221-020, Brazil
  • Novartis Investigative Site
    São Paulo, SP 05403-000, Brazil
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Guang zhou, 510080, China
  • Novartis Investigative Site
    Guangzhou, 510060, China
  • Novartis Investigative Site
    Shanghai, 200025, China
  • Novartis Investigative Site
    Shanghai, 200433, China
  • Novartis Investigative Site
    Hwasun-gun, Jeollanam-do 519-809, Korea, Republic of
  • Novartis Investigative Site
    Daegu, 705-717, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 138-736, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 139-706, Korea, Republic of
  • Novartis Investigative Site
    México, Distrito Federal 06720, Mexico
  • Novartis Investigative Site
    Ekaterinburg, 620036, Russian Federation
  • Novartis Investigative Site
    Moscow, 115478, Russian Federation
  • Novartis Investigative Site
    St. Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    Bangkok, 10330, Thailand
  • Novartis Investigative Site
    Bangkok, 10700, Thailand
  • Novartis Investigative Site
    Khon Kaen, 40002, Thailand
  • Novartis Investigative Site
    Songkla, 90110, Thailand
  • Novartis Investigative Site
    Caracas, Distrito Capital 1010, Venezuela
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2008
First posted
Sep 11, 2008
Start
Jun 2009
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Mar 26, 2014
Last update
Mar 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00751036
Responsible party
Sponsor
First posted
Sep 11, 2008
Start date
Jun 2009
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Mar 26, 2014
Last update
Mar 26, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion